> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Novartis’ Cosentyx
- URL: https://www.fdaweb.com/fda-approves-novartis-cosentyx/
- Published: 2022-01-03T12:00:00.000Z
- Updated: 2026-09-14T17:26:46.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5150813

FDA has approved Novartis’ Cosentyx (secukinumab) to treat active psoriatic arthritis in patients age 2 and older and for active enthesitis-related arthritis in those age 4 and older. The company [says](https://www.healio.com/news/rheumatology/20211223/fda-approves-cosentyx-for-children-with-juvenile-psa-enthesitisrelated-arthritis?ref=fdaweb.com) Cosentyx is the first biologic indicated for enthesitis-related arthritis and the only biologic agent approved for both enthesitis-related arthritis and juvenile psoriatic arthritis in the U.S.

In the Phase 3 JUNIPERA study, juvenile patients with active psoriatic arthritis who received Cosentyx demonstrated a significantly longer time to flare, compared with placebo. Patients with active enthesitis-related arthritis who were treated with the drug also had a longer time to flare. Novartis says safety findings were consistent with the drug’s known profile in treating plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis.